Bevacizumab (BEV), a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF), enhances the antitumor effectiveness of standard chemotherapy in various metastatic cancers, including cancer of the breast, colon, lung and ovary [1]. This evidence concerns the gene VEGFA and breast cancer.